| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
K-Ras G12C-IN-3 targets the mutant K-Ras G12C protein, a well-validated driver mutation in various cancers. It acts as an irreversible/covalent inhibitor, binding to the mutant cysteine residue (G12C) and locking the protein in an inactive GDP-bound state. This prevents the activation of downstream signaling pathways (e.g., MAPK, PI3K) that drive cell proliferation and survival.
|
|---|---|
| ln Vitro |
In vitro, K-Ras G12C-IN-3 is a potent inhibitor of mutant K-Ras G12C. It covalently binds to the G12C mutant protein, inhibiting its activity. It has been shown to inhibit the proliferation of cancer cells harboring the KRAS G12C mutation. However, specific IC₅₀ values are not extensively detailed in the available literature.
|
| ln Vivo |
In vivo, K-Ras G12C-IN-3 has the potential to inhibit tumor growth in KRAS G12C-mutant cancers. However, specific in vivo efficacy data in animal models are not extensively detailed in the available literature. It is a research compound and is not approved for clinical use.
|
| Enzyme Assay |
In vitro KRAS G12C binding assays for K-Ras G12C-IN-3 involve measuring the covalent binding of the compound to the mutant G12C protein. The protein is incubated with varying concentrations of the compound, and the binding is assessed by mass spectrometry or by measuring the inhibition of guanine nucleotide exchange. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for K-Ras G12C-IN-3 are performed using cancer cell lines harboring the KRAS G12C mutation, such as NSCLC or CRC cell lines. Cells are cultured in appropriate media and treated with K-Ras G12C-IN-3 at various concentrations for 48-72 hours. Cell viability is measured by MTT or CellTiter-Glo assays. RAS activity and downstream signaling (e.g., ERK phosphorylation) are assessed by Western blot.
|
| Animal Protocol |
In vivo animal studies for K-Ras G12C-IN-3 would typically involve mouse xenograft models of KRAS G12C-mutant cancers. Immunodeficient mice are injected with cancer cells to establish tumors. When tumors reach a certain size, the compound is administered orally or intraperitoneally. Tumor growth is measured over time. Pharmacodynamic studies assess target engagement and downstream signaling inhibition in tumor tissue.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic properties of K-Ras G12C-IN-3, such as half-life and oral bioavailability, are not extensively detailed in the available literature. As a small molecule with a molecular weight of 453.75 g/mol, it is expected to have moderate oral bioavailability. It is soluble in DMSO (≥30 mg/mL) and is typically formulated for in vivo administration.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for K-Ras G12C-IN-3 are not widely available in public literature. As a research compound, it is intended for laboratory use only and is not for human therapeutic use. Standard safety precautions should be followed when handling this compound. The compound is supplied with a purity of ≥98%.
|
| References | |
| Additional Infomation |
K-Ras G12C-IN-3 is a novel, potent, and irreversible/covalent inhibitor of mutant K-Ras G12C. It is also known as Compound VI-5. The KRAS G12C mutation is present in approximately 14% of NSCLC adenocarcinoma patients and 5% of CRC patients. This product is for research use only.
|
| Molecular Formula |
C21H19CL3N2O3
|
|---|---|
| Molecular Weight |
453.746162652969
|
| Exact Mass |
452.046
|
| CAS # |
1629268-19-4
|
| PubChem CID |
92044410
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
655.0±55.0 °C at 760 mmHg
|
| Flash Point |
349.9±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.604
|
| LogP |
3.39
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
612
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RPBHAPLCWWQJAK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H19Cl3N2O3/c1-3-20(27)25-6-8-26(9-7-25)21(28)16-11-15(18(24)12-19(16)29-2)14-10-13(22)4-5-17(14)23/h3-5,10-12H,1,6-9H2,2H3
|
| Chemical Name |
1-[4-[4-chloro-5-(2,5-dichlorophenyl)-2-methoxybenzoyl]piperazin-1-yl]prop-2-en-1-one
|
| Synonyms |
K-Ras G12C-IN-3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 30 mg/mL (~66.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2039 mL | 11.0193 mL | 22.0386 mL | |
| 5 mM | 0.4408 mL | 2.2039 mL | 4.4077 mL | |
| 10 mM | 0.2204 mL | 1.1019 mL | 2.2039 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA